Our human immune dendritic cells are mature dendritic cells derived from peripheral blood monocytes of ethically consented donors. These cells are generated in vitro by culturing monocytes with GM-CSF and IL-4, followed by maturation using immunostimulatory agents such as LPS, TNF-α, or a cytokine cocktail. The resulting mature dendritic cells exhibit high expression of co-stimulatory molecules (CD80, CD83, CD86) and MHC class II, making them ideal for studies involving T-cell activation, immune response modulation, and antigen presentation.
These immune-competent dendritic cells are widely used in cancer immunotherapy, infectious disease modeling, vaccine adjuvant screening, and T-cell co-culture assays
IDC-Derived Cultured Cells
- 1 mln cells/vial
- Post-thaw viability - ≥ 80%
- ≥ 90% CD11c+, ≥ 90% MHC class II+, ≤ 30% CD83+, and ≤ 5% CD14high by flow cytometry
-
T-cell priming and co-culture assays
-
Cancer immunotherapy and DC-based vaccine studies
-
Pathogen recognition and immune response modeling
-
Cytokine secretion profiling (e.g., IL-12, IL-6, TNF-α)
-